Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00378001
Recruitment Status : Completed
First Posted : September 19, 2006
Last Update Posted : February 16, 2015
Information provided by:
IBSA Institut Biochimique SA

September 15, 2006
September 19, 2006
February 16, 2015
March 2005
May 2006   (Final data collection date for primary outcome measure)
The primary endpoint is the total number of oocytes retrieved.
Same as current
Complete list of historical versions of study NCT00378001 on Archive Site
  • Total FSH dose (IUs);number of days of FSH stimulation and stimulation duration;number of follicles >14 mm on the day of hCG injection;
  • 17-β estradiol (E2) serum concentration on the day of hCG injection;cancellation rate with reasons;
  • Fertilization rate: number of 2PN (or already cleaved) embryos;
  • Total number of embryos,number transferred, frozen and discarded;implantation rate;number of transferred embryos; clinical pregnancy rate, per stimulated cycle, per oocyte retrieval and per embryo transfer.
Same as current
Not Provided
Not Provided
Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF
A Prospective, Multicenter, Investigator Blinded, Randomized, Concurrent Control Study of Efficacy and Tolerability of Two FSH Preparations (Fostimon® Versus Gonal-F®) in Women Undergoing IVF
The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous FSH preparations (Fostimon®, IBSA vs Gonal-F®, Serono Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.
This is a prospective, multicenter, investigator blinded, randomized, concurrent control, phase III clinical trial. Patients meeting the eligibility requirements of the study will be randomly assigned to receive either the test drug (Fostimon®, IBSA) or the reference drug (Gonal-F®, Serono Inc.). Investigators will be blinded by not allowing them to have any contact with the study medications (supplied in boxes labeled in a manner that does not reveal the content of the boxes), and requesting that patients do not make any statements to the investigator that might indicate the treatment to which they were assigned. Equivalence testing with regard to the primary outcome variable will establish whether the two treatments are indeed similarly effective.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Drug: FSH-IBSA
  • Drug: GONAL-F
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
May 2006
May 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • >/=18 and <40 years old;

    • BMI between 18 and 30 kg/m2;
    • less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery);
    • basal FSH <10 IU/L and E2 <80 pg/mL;
    • Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, sonohysterogram, or hysteroscopic examination;
    • >10 antral follicles 2-10 mm in size;
    • Normal or clinically insignificant hematology and blood chemistry values. TSH levels must be within the normal limits for the testing laboratory, or the patient should be euthyroid as determined by the investigator (e.g. normal free thyroxine). TSH can be low secondary to exogenous thyroid medication where patient is euthyroid;
    • Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule.

Exclusion Criteria:

  • · age <18 and >/=40 years;

    • primary ovarian failure or women known as poor responders (i.e. requiring more than 300 IU of FSH as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an E2 serum concentration <1800 pmol/L/500pg/mL);
    • prior ovarian hyperstimulation syndrome (OHSS), polycystic ovarian syndrome that would normally be started at a lower FSH dose than is initially required by the study (i.e. 300 IU), or likely intolerance to even two days of 300 IU FSH.
    • one or both ovaries inaccessible for oocyte retrieval;
    • ovarian cysts >20 mm;
    • hydrosalpinx that have not been surgically removed or ligated;
    • stage 3 or 4 endometriosis;
    • oocyte donation;
    • implantation of previously frozen embryos;
    • patients affected by pathologies associated with any contraindication of being pregnant;
    • hypersensitivity to the study medication;
    • abnormal bleeding of undetermined origin;
    • uncontrolled thyroid or adrenal dysfunction;
    • neoplasias;
    • severe impairment of renal and/or hepatic function;
    • use of concomitant medications that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents).
Sexes Eligible for Study: Female
18 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
IBSA Institut Biochimique SA
Not Provided
Principal Investigator: Valerie Baker, MD Fertility Physicians of Northern California
Principal Investigator: Victor Y Fujimoto, MD UCSF In Vitro Fertilization
Principal Investigator: L. Michael Kettel, MD San Diego Fertility Center
Principal Investigator: Michael R Soules, MD Seattle Reproductive Medicine
IBSA Institut Biochimique SA
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP